Literature DB >> 11528229

Cerebral imaging changes in patients with chronic renal failure treated conservatively or in hemodialysis.

G M Savazzi1, F Cusmano, S Musini.   

Abstract

BACKGROUND: Nonuremic patients with apparently normal memory and behavior, studied by means of cerebral computed tomography and found to have cerebral atrophy (CA), evidenced functional intellectual deficits when they underwent psychometric testing. The finding of CA has been repeatedly reported in limited case groups of uremic patients who also demonstrated functional intellectual deficits on the basis of the same tests. This retrospective study considered all diagnostic cerebral computed tomography scans done in our department between 1981 and 1998. Fifty-five uremic patients in conservative treatment (CT) and 111 patients in hemodialysis treatment (HT) were selected on the basis of the following two criteria: primary nephropathy as the cause of uremia and an age < or =55 years to exclude involutive brain changes occurring with age. AIMS: The aims of the study were to determine the percent of uremic patients with CA, the characteristics of their CA (cortical or subcortical), and eventual associated morphological lesions.
RESULTS: CA was detected in 50.9% (cortical atrophy in 47.3% and subcortical atrophy in 3.6%) of the uremic patients in CT and in 77.5% of those in HT (cortical atrophy in 65.7% and subcortical atrophy in 7.7%). The average degree of CA was 0.872 in the patients in CT and 1.765 in the patients in HT. Thirty-four of the patients in the CT group and 46 in the HT group were hypertensive: these patients had a more severe degree of CA than the nonhypertensive subjects. In the CT group, the degree of CA in the hypertensive patients was 1.205 versus 0.428 for the nonhypertensive subjects. In the HT group, the degree of CA was 2.087 for the hypertensive patients versus 1.538 for the nonhypertensive patients. Of the overall population, 7.8% had ischemic lesions, 9.6% had endocranial calcifications, and 5.4% evidenced periventricular white matter hyperintensities.
CONCLUSIONS: The high percent of CA found in young uremic patients increased in subjects in HT and, even more so in hypertensive patients. Vascular calcifications, focal ischemia and leukoaraiosis, well-known expressions of a chronic state of cerebrovascular insufficiency, were also found in HT patients; hypertension alone is a recognized accelerator of vascular damage. Thus, early and severe atherosclerosis and related hypoperfusion can be considered as the paramount causes of parenchymal cerebral damage in uremia. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11528229     DOI: 10.1159/000046040

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  24 in total

1.  Comparison of Subdural Hematoma Risk between Hemodialysis and Peritoneal Dialysis Patients with ESRD.

Authors:  I-Kuan Wang; Yu-Kai Cheng; Cheng-Li Lin; Chiao-Ling Peng; Che-Yi Chou; Chiz-Tzung Chang; Tzung-Hai Yen; Chiu-Ching Huang; Fung-Chang Sung; Chung Y Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

2.  Cerebral metabolic changes in neurologically presymptomatic patients undergoing haemodialysis: in vivo proton MR spectroscopic findings.

Authors:  Ming-Lun Chiu; Chun-Wei Li; Jer-Ming Chang; I-Chan Chiang; Chih-Hung Ko; Hung-Yi Chuang; Reu-Sheng Sheu; Chen-Chang Lee; Tsyh-Jyi Hsieh
Journal:  Eur Radiol       Date:  2009-12-08       Impact factor: 5.315

3.  Inflammatory markers and risk of cerebrovascular events in patients initiating dialysis.

Authors:  Stephen M Sozio; Josef Coresh; Bernard G Jaar; Nancy E Fink; Laura C Plantinga; Paige A Armstrong; J Craig Longenecker; A Richey Sharrett; Neil R Powe; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-05       Impact factor: 8.237

4.  Preserved Cerebral Oxygenation with Worsening Global Myocardial Strain during Pediatric Chronic Hemodialysis.

Authors:  Alexandra Idrovo; Ricardo Pignatelli; Robert Loar; Asela Nieuwsma; Jessica Geer; Catharina Solomon; Sarah Swartz; Nancy Ghanayem; Ayse Akcan-Arikan; Poyyapakkam Srivaths
Journal:  J Am Soc Nephrol       Date:  2021-09-13       Impact factor: 10.121

5.  Inhibitory effect of CUL1 on atherosclerosis through the p53 pathway.

Authors:  Xi Zhang; Youwei Lu; Wei Jiang; Qianhong Yang
Journal:  Ann Transl Med       Date:  2022-09

6.  Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for Basal Ganglia calcification in hypoparathyroidism.

Authors:  Ravinder Goswami; Tabin Millo; Shruti Mishra; Madhuchhanda Das; Mansi Kapoor; Neeraj Tomar; Soma Saha; Tara Shankar Roy; Vishnubhatla Sreenivas
Journal:  J Clin Endocrinol Metab       Date:  2014-02-19       Impact factor: 5.958

Review 7.  Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden.

Authors:  Anne M Murray
Journal:  Adv Chronic Kidney Dis       Date:  2008-04       Impact factor: 3.620

8.  Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study.

Authors:  Stephen M Sozio; Paige A Armstrong; Josef Coresh; Bernard G Jaar; Nancy E Fink; Laura C Plantinga; Neil R Powe; Rulan S Parekh
Journal:  Am J Kidney Dis       Date:  2009-04-19       Impact factor: 8.860

9.  Predominant gray matter volume loss in patients with end-stage renal disease: a voxel-based morphometry study.

Authors:  Long Jiang Zhang; Jiqiu Wen; Ling Ni; Jianhui Zhong; Xue Liang; Gang Zheng; Guang Ming Lu
Journal:  Metab Brain Dis       Date:  2013-09-26       Impact factor: 3.584

10.  Voxel-based morphometry and arterial spin labeling fMRI reveal neuropathic and neuroplastic features of brain processing of itch in end-stage renal disease.

Authors:  Alexandru D P Papoiu; Nichole M Emerson; Tejesh S Patel; Robert A Kraft; Rodrigo Valdes-Rodriguez; Leigh A Nattkemper; Robert C Coghill; Gil Yosipovitch
Journal:  J Neurophysiol       Date:  2014-06-18       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.